Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 23;54(12):4119-32.
doi: 10.1021/jm200153p. Epub 2011 May 23.

Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

Affiliations

Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication

Andrew V Stachulski et al. J Med Chem. .

Abstract

We report the syntheses and activities of a wide range of thiazolides [viz., 2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis B virus replication, with QSAR analysis of our results. The prototypical thiazolide, nitazoxanide [2-hydroxybenzoyl-N-(5-nitrothiazol-2-yl)amide, NTZ] 1 is a broad spectrum antiinfective agent effective against anaerobic bacteria, viruses, and parasites. By contrast, 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide 3 is a novel, potent, and selective inhibitor of hepatitis B replication (EC(50) = 0.33 μm) but is inactive against anaerobes. Several 4'- and 5'-substituted thiazolides show good activity against HBV; by contrast, some related salicyloylanilides show a narrower spectrum of activity. The ADME properties of 3 are similar to 1; viz., the O-acetate is an effective prodrug, and the O-aryl glucuronide is a major metabolite. The QSAR study shows a good correlation of observed EC(90) for intracellular virions with thiazolide structural parameters. Finally we discuss the mechanism of action of thiazolides in relation to the present results.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Basic thiazolide structures 1-3.
Figure 2
Figure 2
Thiazolide O-glucuronides.
Figure 3
Figure 3
Predicted vs Experimental pEC90 RI as predicted by the QSAR model01A for pEC90 RI.
Scheme 1
Scheme 1
a General synthetic procedures for thiazolides. a i) Coupling step: Carboxylic acid reacted with SOCl2/ pyridine or (COCl)2/ DMF, DCM, then either add acid Cl to amine in aq. NaHCO3 organic solvent with stirring, or add to amine in dry THF with Et3N: or BrPyBOP or BOP-Cl, NMM, CH2Cl2; deprotection: aq. HCl, 60°C or aq. NH3.
Scheme 2
Scheme 2
a Syntheses of 5′-acetamido and 5′-fluorothiazolides a i) H2-Raney Ni, Ac2O; ii) aq. NH3; iii) SelectFluor, MeCN, heat; iv) aq. NaOH/EtOH.
Scheme 3
Scheme 3
a Syntheses of 4′-and 5′- methanesulfonylthiazolides a i) MeSO2Na, CuI, DMF, heat; ii) MeSNa, EtOH; iii) acetylsalicyloyl chloride; iv) 3-ClC6H4CO3H (2 eq.); v) aq. NH3.
Scheme 4
Scheme 4
a Syntheses of 5′- aryl, alkyl, cyano and methoxycarbonylthiazolides. a i) N-bromosuccinimide, MeOH; ii), iii) (H2N)2C=S.
Scheme 5
Scheme 5
a Synthesis of 5′-trifluoromethylthiazolide 28. a) i) MCPBA, K2CO3, CH3CN, RT to 40 0C; ii) NH2C(=S)NH2 (2 equiv.) DMF, 75 0C; iii) Acetylsalicyloyl chloride, Et3N, CH2Cl2; iv) HCl, H2O, THF, 50 0C
Scheme 6
Scheme 6
a Synthesis of the O-glucuronide of 3. a i) 2-amino-5-chlorothiazole hydrochloride, NMM, EDCI, DMAP, HOBt, CH2Cl2; ii) NaOH, aq. MeOH, then pH 6.

Similar articles

Cited by

References

    1. Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J. Hepatol. 2009;50:805–816. - PubMed
    1. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970:695–698. - PubMed
    2. Summers J, O’Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc. Nat. Acad. Sci. USA. 1975;72:4597–4601. - PMC - PubMed
    1. Blumberg BS. Australia Antigen and the Biology of Hepatitis B. Science. 1977;197:17–25. - PubMed
    1. Poland GA. Evaluating existing recommendations for hepatitis A and B vaccination. Am. J. Med. 2005;118(10A):16S–20S. - PubMed
    2. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med. 2001;135:796–800. - PubMed
    1. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5Å resolution of HIV reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790. - PubMed

Publication types

MeSH terms